You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 20, 2025

Claims for Patent: 10,736,965

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,736,965

Title:	Risperidone biodegradable implant
Abstract:	The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
Inventor(s):	Siegel Steven, Winey Karen
Assignee:	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Application Number:	US16174083
Patent Claims:	1. A biodegradable implant comprising:a) a therapeutic drug present in an amount of 10-60% by mass relative to the mass of the implant, andb) a polymer present in an amount of 40-90% by mass relative to the mass of the implant,wherein the polymer comprises PLA and optionally PGA in a PLA:PGA molar ratio between 50:50 and 100:0;wherein the therapeutic drug is risperidone;wherein the implant is a shape suitable for tolerability in the subcutaneous space; andwherein the mass of the implant is from 0.1-1.1 g.2. The implant of claim 1 , wherein the risperidone is present at a concentration of 20-30% by mass relative to the mass of the implant.3. The implant of claim 1 , wherein the polymer comprises PLA polymer.4. The implant of claim 2 , wherein the polymer comprises PLA polymer.5. The implant of claim 1 , wherein the polymer comprises PLGA polymer.6. The implant of claim 2 , wherein the polymer comprises PLGA polymer.7. The implant of claim 6 , wherein the PLGA has a molar ratio of lactic monomer to glycolic monomer of 80:20.8. The implant of claim 6 , wherein the PLGA has a molar ratio of lactic monomer to glycolic monomer of 75:25.9. The implant of claim 6 , wherein said PLGA has a molar ratio of lactic monomer to glycolic monomer of 65:35.10. The implant of claim 1 , further comprising a pharmaceutically acceptable excipient.11. The implant of claim 2 , further comprising a pharmaceutically acceptable excipient.12. The implant of claim 2 , wherein the mass of the implant is from 0.1-0.3 g.13. The implant of claim 2 , wherein the mass of the implant is from 0.5-1.0 g.14. The implant of claim 2 , wherein the mass of the implant is from 0.6-0.8 g.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.